UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

UCLA Institute of Urologic Oncology

Our Expert Team


PDF | Flipbook

Our Expert Team

Board of Directors

Arie Belldegrun, MD: Director of Institute of Urologic Oncology at UCLA.

Arie Belldegrun, MD

Mark Litwin, MD, MPH: Chair of UCLA Department of Urology.

Mark S. Litwin, MD, MPH

Jonathan Braun, MD: Chair of UCLA Department of Pathology & Laboratory Medicine.

Jonathan Braun, MD

Dennis Slamon, MD: Chief of UCLA Division of Hematology Oncology.

Dennis Slamon, MD, PhD
Medical Oncology

Michael Steinberg, MD: Chair of the UCLA Department of Radiation Oncology.

Michael Steinberg, MD
Radiation Oncology

Judith Gasson

Judith Gasson, PhD
Associate Dean

IUO Experts

Urologic Oncology  |  Medical Oncology  |  Pathology  |  Radiation Oncology  |  Radiology  |  Research  |  Clinical Trials

Urologic Oncology

  Arie Belldegrun, MD, FACS - Director Arie Belldegrun, MD, FACS - Director

Dr. Belldegrun is the Director of the Institute of Urologic Oncology at UCLA; Professor of Urology; Chief, Division of Urologic Oncology; and Founder and Surgical Director, UCLA Kidney Cancer Program(www.kidneycancer.ucla.edu).  He also holds the Roy and Carol Doumani Chair in Urologic Oncology and serves as the Director of the Urologic Oncology Fellowship Program at UCLA.  Dr. Belldegrun's surgical expertise encompasses all aspects of urologic oncology, including kidney, prostate, bladder and testicular cancers.  He has authored over 400 peer-reviewed publications, books and book chapters in the area of localized and advanced kidney and prostate cancers.  Dr. Belldegrun is a world-renown expert in complicated kidney cancer surgeries, and has unique expertise in a variety of surgical approaches to small renal tumors including open, laparoscopic, robotic partial nephrectomy and cryotherapy.  He is also a recognized expert in minimally invasive and focal prostate cancer therapy, specifically cryo-surgical prostate cancer ablation, and he has published extensively his UCLA experience with cryotherapy.  Dr. Belldegrun's research lab at UCLA focuses on the development of personalized cancer immunotherapy and targeted cancer vaccines for the treatment of kidney cancer.

  Karim Chamie, MD Karim Chamie, MD, MSHS

Assistant Professor-in-Residence or Urology. Dr. Chamie attended medical school at USC and completed his urological training at UC Davis.  He then completed a combined health services research and urologic oncology fellowship at UCLA.  Dr. Chamie's primary research interests include quality of care for patients with urologic malignancies.  His clinical interests include all areas of urologic oncology, with a particular emphasis on bladder cancer.

  Arnold I. Chin, MD, PhD

Dr. Chin is Assistant Professor of Urology. Dr. Chin completed his residency training program at UCLA.  His clinical interests include urologic oncology, with an emphasis on bladder cancer.  He performs open, laparoscopic, and robotically-assisted surgery for bladder, prostate and renal malignancies.

  Jean B. deKernion, MD

Professor of Urology. Residency, Case Western Reserve in Cleveland, fellowship, National Cancer Institute. Certified by the American Board of Surgery and American Board of Urology. World leader in Urologic Oncology, co-authored the first textbook on the subject. Founder, Society of Urologic Oncology, member of the American Board of Urology, Chair, Department of Defense prostate cancer Research program. Kidney, bladder and prostate cancer are the areas in which he has made the most significant contributions.

  Isla Garraway, MD, PhD Isla Garraway, MD, PhD

Assistant Professor of Urology at UCLA, Attending Urologist, Greater Los Angeles - VA Medical Center.  Dr. Garraway's primary clnical and research focus is on prostate cancer. Sheis a member of the Jonsson Comprehensive Cancer Center and heads a laboratory investigating prostate development and carcinogenesis.

  Dr. Holden

Stuart Holden, MD

Dr. Holden is a Health Sciences Clinical Professor of Urology and Associate Director, UCLA Institute of Urologic Oncology. Dr. Holden is recognized as an expert in prostate cancer research throughout the medical community, and was named medical director of the Prostate Cancer Foundation. Prior to joining UCLA, Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai Medical Center.


  Mark S. Litwin, MD, MPH

Chair, Department of Urology. Professor of Urology and Public Health. He trained at Harvard and specializes in testicular, bladder, prostate and kidney cancer. Dr. Litwin's research focuses on improving quality of care and quality of life in urologic oncology. He leads Urologic Diseases in America (www.udaonline.net), the NIH's largest effort at documenting the burden of urologic diseases on the American people. He also created and directs IMPACT, a state-funded program that provides free medical care statewide for low-income, uninsured men with prostate cancer (www.california-impact.org).

  Leonard S. Marks, MD

Dr. Marks is a Professor of Urology, completed his training at UCLA in 1978.  He received an American Foundation of Urologic Diseases scholarship award and a Prostate Cancer Foundation research award.  He current research interests involve prostate markers, imaging and minimally-invasive treatments.

  Allan Pantuck, MD, MS, FACS

Dr. Pantuck is the Director of Translational Research for the UCLA Kidney Cancer Program.  He is an Associate Professor of Urology and in the spring of 2007 was appointed as Director of Genitourinary Oncology at UCLA's Jonsson Comprehensive Cancer Center.  Dr. Pantuck earned his BS from Columbia University, his MD from University of Medicine and Dentistry of New Jersey and his MS from the David Geffen School of Medicine at UCLA.  Dr. Pantuck's research interests focus primarily in translational research in genitourinary oncology, such as nutrition and chemo prevention.

  Robert E. Reiter, MD

Professor, Urology, Molecular Biology, Director of the Prostate Cancer Program, Director of Urologic Research, Co-Director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. Attended Stanford Medical School, completed urologic training at Stanford and Baylor College of Medicine, completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute. His clinical interests include all areas of urologic oncology, with an emphasis on prostate cancer. He specializes in robotically-assisted prostatectomy and cystectomy, as well as open surgery, with robotic experience dating back to 2004, for bladder, prostate, and renal malignancies. Dr. Reiter is involved in all aspects of urologic oncology, with an emphasis on prostate cancer, and brings extensive experience in robotic surgery and the applications of translational research and the latest in MRI and molecular imaging to the management of men with this disease.

  Christopher Saigal, MD, MPH

Dr. Saigal is Associate Professor of Urology. His clinical practice is at both the UCLA Westwood and Santa Monica campuses. Dr. Saigal has had a longstanding clinical focus in urologic cancers. His research is focused on ways to improve treatment decisions by incorporating patient values and quality of care for urologic cancers.


  Robert B. Smith, MD

Dr. Smith is an Assistant Professor of Urology and Chief of the Renal Transplant service.  Dr. Smith earned his MD for the UCLA School of Medicine.  He served in the Air Force and Lieutenant Colonel, Chief of Urology at Lackland Air Force Base.  Dr. Smith's clinical interests are in the treatment of urologic malignancies and in reconstructive urologic cases.


Medical Oncology

  Alexandra Drakaki, MD

Alexandra Drakaki, MD

Dr. Drakaki is a faculty at UCLA in the Department Medicine, division of Hematology/Oncology. She performed her residency in Internal Medicine in a Tuft's University affiliate program while she completed her Hematology and Oncology fellowship in Beth Israel Deaconess Center at Harvard Medical School. She specializes in breast cancer as well as genitourinary malignancies including primarily bladder, testicular, prostate, urethral, penile and kidney cancer. Dr. Drakaki's research focuses on identifying the therapeutic potential of novel genes named micro-RNAs that are involved in bladder carcinogenesis and other solid malignancies. She is also participating and running clinical trials specific to the aforementioned malignancies.

  Fairooz Kabbinavar, MD

Dr. Kabbinavar the Medical Director of the UCLA Kidney Cancer Program, and Professor of Medicine in the Division of Hematology Oncology.  He earned h is MD from the University of Nagpur Faculty of Medicine, India; and completed his Fellowship in Hematology-Oncology at the UCLA School of Medicine.  Dr. Kabbinavar's research focuses on anti-tumor angiogenesis and translational work.  His clinical interests focus on kidney cancer, lung cancer and head and neck cancer.

  Matthew Rettig, MD

Dr. Rettig is a Professor in the Department of Medicine, Division of Hematology-Oncology, and the Department of Urology, and is the Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology.  Dr. Rettig earned his MD from Duke University. He completed his fellowship in Hematology-Oncology at the David Geffen School of Medicine at UCLA.  Dr. Rettig's primary focus is on the management of genitourinary malignancies, with a clinical emphasis on advanced prostate cancer and research emphasis on identifying biochemical targets for the therapeutic translation in castration-resistant prostate cancer and clear cell renal cell carcinoma.  Dr. Rettig also served as the Director of the Clinical Trials Program in Prostate Cancer at UCLA.



  Jiaoti Huang, MD, PhD

Dr. Huang is the Director of Urologic Pathology and Professor of Pathology and Laboratory Medicine.  He earned his MD from Anhui University, in Hefei, China and completed his Fellowship in Anatomic and Clinical Pathology at Memorial Sloan-Kettering Cancer Center in New York. Dr. Huang's primary focus is on Genitourinary Pathology, Surgical Pathology, and Urologic Pathology.

  Dr. Rao Jian Yu Rao, MD

Dr. Rao is a Professor Pathology and Epidemiology, Chief of Cytopathology and Director of the Gynecological Pathology.  Dr. Rao received his MD from Shanghai University.  He completed his Fellowships at UCLA School of Medicine and University of Oklahoma College of Medicine.

  Nagesh P. Rao, PhD, FACMG

Dr. Rao is Chief, clinical and Molecular Cytogenetics Laboratory, Molecular Pathology, Cytogenetics and Orphan Disease.  He is also Professor of Pathology and Laboratory Medicine.

  Jonathan Said, MD

Dr. Said is Professor of Pathology and Laboratory Medicine, Chief of Anatomic and Surgical Pathology and Chief of Genitourinary Pathology.  Dr. Said earned his MD from the University of the Witwatersrand Medical School in Johannesburg and completed his Residency and Fellowship in Hematopathology at Harvard's Brigham & Women's Hospital.  Dr. Said is an expert in the pathology diagnosis of urologic diseases and has published extensively on neoplastic diseases of the kidney and prostate.


Radiation Oncology

  Mitchell Kamrava, MD

Mitchell Kamrava, MD

Dr. Kamrava is an Assistant Clinical Professor in the UCLA Radiation Oncology Department.  He graduated from the University of California, San Diego (UCSD) Medical School.  He completed his internship in internal medicine at Stanford University Hospital and his residency in radiation oncology at the NCI, where he served as chief resident. He then completed a brachytherapy fellowship at the UCLA. His clinical interests include prostate brachytherapy, Functional Image-Guided Radiation Therapy (Functional IGRT) and Intensity Modulated Radiation Therapy (IMRT).

  Dr. King Christopher King, MD, PhD

Dr. King is Associate Professor of Radiation Oncology and Urology at UCLA. Dr. King received his MD from Boston University, and completed his residency training in Radiation Oncology at Yale University.  Before joining UCLA, he was Associate Professor at Stanford.  Dr. King also holds a PhD in Astrophysics from Yale University.  He specializes in the treatment of genitourinary cancers and has pioneered the use of stereotactic body radiation therapy (BRT) for the treatment of prostate cancer.  He research explores novel treatment techniques for prostate, kidney and bladder cancer.

  Patrick Kupelian, MD

Dr. Kupelian is a Professor of Radiation Oncology and Vice-Chair of Clinical Operations and clinical Research at UCLA. He completed his Residency training in Radiation Oncology at the University of Texas M.D. Anderson Cancer Center and his Fellowship in Radiation Oncology at the Cleveland Clinic Foundation. Dr. Kupelian specializes in genitourinary malignancies and has pioneered high-does hypofractionated radiation therapy for prostate cancer.



  Daniel Margolis, MD Daniel Margolis, MD

Dr. Margolis is in charge of virtual colonography at UCLA. He is interested in the use of MRI for characterization of cancer and efficacy of treatment. Dr. Daniel Margolis is also co-director of prostate magnetic resonance imaging.

  Dr. Raman Steven Raman, MD

Dr. Steven Raman is a Professor of Radiology and Urology and is an expert in Urological Radiology, having published over 75 papers, 100 abstracts and several book chapters in this field. He has been the founding member of the UCLA Prostate Imaging Group, whose members include physicians and scientists dedicated to advancing the field of prostate imaging. Dr. Raman believes that MR imaging the best non-invasive solution for finding the most aggressive prostate cancer.


  Lily Wu, MD, PhD

Faculty member, Urology since 1998. Graduated, member of the inaugural class of Medical Scientist Training Program (M.D., Ph.D. program). Her education training ranges from clinical disciplines such as pediatrics and hematology/oncology to molecular and cellular fields such as adenovirus biology, transcription regulation, and gene therapy. Besides her research endeavors, a major part of her effort involves mentoring students at all levels, from undergraduates, graduate, postdoctoral fellows to clinical residents.

  Gang Zeng, PhD

Associate Professor in Urologic Oncology and Member of the Jonsson Comprehensive Cancer Center. His current work is focused on cancer immunodiagnosis, immunotherapy, and prostate cancer stem cell biology.


Clinical Trials

  Nazy Zomorodian, RNC, MSN, CUNP, CCRC

Ms. Zomorodian is the Director of the Genitourinary Clinical Trials and a Nurse Practitioner for the Department of Urology.  She received her BS and Masters of Science in Nursing from the Hahnermann University in Philadelphia and is working on her PhD in Research Nursing at UCLA.  Ms. Zomorodian is also certified by the Association of Clinical Research Professional as a Clinical Research Coordinator. She has extensive experience in managing and conducting cancer research and she also works closely with UCLA's urologic and medical oncology principal investigators in basic research.  Ms. Zomorodian regularly instructs physicians, fellows, residents and nurses on all aspects of clinical trials for kidney, prostate and bladder cancers.

See current clinical trials »

UCLA Rated One of the Top Hospitals in the Nation